据外媒报道,一项发表在《 International Journal of Antimicrobial Agents》 The new study found early evidence that a combination of hydroxychloroquine, an popular antimalarial drug Plaqenuil, and the antibiotic Zithromax or Azithrocin may be effective in treating new coronary pneumonia and shorten the infection time of the virus in patients.
The researchers divided patients diagnosed with new coronary pneumonia into three groups, one using only hydroxychloroquine, one group using a combination of hydroxychloroquine and antibiotics, and one group not using the two drugs (control group). The study found that the second group of drug-giving programs can reduce the time of infection in patients.
Of the patients involved in the study, 6 had no symptoms, 22 had upper respiratory symptoms such as sneezing, headache and sore throat, and 8 had lower respiratory symptoms — mainly coughing. While hydroxychloroquine was effective as a separate treatment, the results were better and had a significant advantage when used in combination with azithromycin, and the results showed that 20 of the 30 participants in the study had been treated.
But these results represent only a limited study of a small number of patients, but they are promising, especially in combination with the same treatment programs that were reported early in Chinese patients. Now researchers from around the world are testing for possible treatments, including a range of drugs previously used to fight Ebola, SARS, AIDS and other global outbreaks.